Real-world Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the United States
PhD Mindy M Cheng, PhD Carolina Reyes, PhD Sacha Satram, PhD Helen Birch, MB Daniel C Gibbons, MPH Myriam Drysdale, Christopher F Bell, PhD Anvar Suyundikov, PhD Xiao Ding, M Cyrus Maher, MD Wendy Yeh, MD, PhD Amalio Telenti, MD Lawrence Corey
doi:10.1101/2022.09.07.22279497
Background Sotrovimab, a recombinant human monoclonal antibody (mAb) against SARS-CoV-2 had US FDA Emergency Use Authorization (EUA) for the treatment of high-risk outpatients with mildto-moderate COVID-19 from May 26, 2021 to April 5, 2022. The study objective was to evaluate the real-world effectiveness of sotrovimab in reducing the risk of 30-day all-cause hospitalization and/or mortality during the time period when the prevalence of circulating SARS-CoV-2 variants was changing between Delta and Omicron sub-lineages in the US.
Methods A retrospective analysis was conducted on de-identified claims data for 1,530,501 patients diagnosed with COVID-19 (ICD-10: U07.1) from September 1, 2021, to April 30, 2022, in the FAIR Health National Private Insurance Claims (FH NPIC ® ) database. Patients meeting EUA high-risk criteria were identified via pre-specified ICD-10-CM diagnoses in records ≤24 months prior to their first COVID-19 diagnosis and divided into two cohorts based on claimed procedural codes: treated with sotrovimab ("sotrovimab") and not treated with a mAb ("no mAb"). All-cause hospitalizations and facility-reported all-cause mortality within 30 days of diagnosis ("30-day hospitalization or mortality") were identified. Multivariable and propensity score-matched Poisson and logistic regressions were conducted to estimate the adjusted relative risk (RR) and odds of 30-day hospitalization or mortality among those treated with sotrovimab compared with those not treated with a mAb.
Results Of the high-risk COVID-19 patients identified, 15,633 were treated with sotrovimab and 1,514,868 were not treated with a mAb. Compared with the no mAb cohort, the sotrovimab All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
References
Aggarwal, Beaty, Bennett, Change in Effectiveness of Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients During the Omicron Phase, MedRxiv,
doi:10.1101/2022.06.17.22276575
Aggarwal, Beaty, Bennett, Real-World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients, JID,
doi:10.1093/infdis/jiac206
Case, Mackin, Errico, Resilience of S309 and AZD7442 Monoclonal Antibody Treatments Against Infection by SARS-CoV-2 Omicron Lineage Strains, Nature Communications
Cathcart, Havenar-Daughton, Lempp, The Dual Function Monoclonal Antibodies VIR-7831 and VIR-7832 Demonstrate Potent in Vitro and in Vivo Activity Against SARS-CoV-2, BioRxiv,
doi:10.1101/2021.03.09.434607
Covid-, Estimating Excess Mortality Due to the COVID-19 Pandemic: a Systematic Analysis of COVID-19 Related Mortality, Lancet
Elbe, Buckland-Merrett, Data, Disease and Diplomacy: GISAID's Innovative Contribution to Global Health, Global Challenges
Gavriatopoulou, Ntanasis-Stathopoulous, Korompoki, Emerging treatment strategies for COVID-19 infection, Clin Exp Med
Gupta, Gonzalez-Rojas, Juarez, Early Treatment for COVID-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab, NEJM
Gupta, Gonzalez-Rojas, Juarez, Effect of Sotrovimab on Hospitalization or Death Among High-Risk Patients with Mild to Moderate COVID-19, A Randomized Clinical Trial, JAMA
Lee, Wong, Chai, Efficacy of COVID-19 Vaccines in Immunocompromised Patients: Systemic Review and Meta-analysis, BMJ
Parker, Desai, Marti, Response to Additional COVID-19 Vaccine Doses in People who are Immunocompromised: a Rapid Review, The Lancet Global Health
Telenti, Hodcroft, Robertson, The Evolution and Biology of SARS-CoV-2 Variants, Cold Spring Harb Perspect Med
Zaqout, Almaslamani, Chemaitelly, Effectiveness of the Neutralizing Antibody Sotrovimab Among High-risk Patients With Mild to Moderate SARS-CoV-2 in Qatar, MedRxiv,
doi:10.1101/2022.04.21.22274060